Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Antihormonal treatment associated musculoskeletal pain in women with breast cancer in the adjuvant setting.

Seber S, Solmaz D, Yetisyigit T.

Onco Targets Ther. 2016 Aug 9;9:4929-35. doi: 10.2147/OTT.S108968. eCollection 2016.

2.

Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer.

Qiu L, Fu F, Huang M, Lin Y, Chen Y, Chen M, Wang C.

Sci Rep. 2016 May 27;6:26627. doi: 10.1038/srep26627.

3.

Incidence of metabolic syndrome in breast cancer survivors on adjuvant hormonal therapy.

Kate A, Kadambari D.

J Pharmacol Pharmacother. 2016 Jan-Mar;7(1):28-30. doi: 10.4103/0976-500X.179362. No abstract available.

4.

Clinical utility of letrozole in the treatment of breast cancer: a Chinese perspective.

He DX, Ma X.

Onco Targets Ther. 2016 Mar 1;9:1077-84. doi: 10.2147/OTT.S81087. eCollection 2016. Review.

5.

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial.

Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Coleman RE.

J Bone Oncol. 2012 Jul 11;1(2):57-62. doi: 10.1016/j.jbo.2012.06.002. eCollection 2012 Sep.

6.

Prevention and treatment of bone fragility in cancer patient.

Ottanelli S.

Clin Cases Miner Bone Metab. 2015 May-Aug;12(2):116-29. doi: 10.11138/ccmbm/2015.12.2.116. Epub 2015 Oct 26. Review.

7.

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.

Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell'Orto P, Biasi MO, Thürlimann B, Harvey V, Neven P, Arnould L, Maibach R, Price KN, Coates AS, Goldhirsch A, Gelber RD, Pagani O, Viale G, Rae JM, Regan MM; BIG 1-98 Collaborative Group.

Breast Cancer Res Treat. 2015 Dec;154(3):543-55. doi: 10.1007/s10549-015-3634-6. Epub 2015 Nov 21.

PMID:
26590813
8.

Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design.

Mirzaie S, Chupani L, Asadabadi EB, Shahverdi AR, Jamalan M.

EXCLI J. 2013 Mar 11;12:168-83. eCollection 2013.

9.

Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Munzone E, Giobbie-Hurder A, Gusterson BA, Mallon E, Viale G, Thürlimann B, Ejlertsen B, MacGrogan G, Bibeau F, Lelkaitis G, Price KN, Gelber RD, Coates AS, Goldhirsch A, Colleoni M; International Breast Cancer Study Group and the BIG 1-98 Collaborative Group.

Ann Oncol. 2015 Dec;26(12):2442-9. doi: 10.1093/annonc/mdv391. Epub 2015 Sep 19.

PMID:
26387144
10.

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance.

Servitja S, Martos T, Rodriguez Sanz M, Garcia-Giralt N, Prieto-Alhambra D, Garrigos L, Nogues X, Tusquets I.

Ther Adv Med Oncol. 2015 Sep;7(5):291-6. doi: 10.1177/1758834015598536. Review.

11.

Predicting benefit of endocrine therapy for early breast cancer.

Regan MM.

Breast. 2015 Nov;24 Suppl 2:S129-31. doi: 10.1016/j.breast.2015.07.029. Epub 2015 Aug 5.

PMID:
26255197
12.

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.

Wang J, Lu K, Song Y, Zhao S, Ma W, Xuan Q, Tang D, Zhao H, Liu L, Zhang Q.

PLoS One. 2015 Jul 28;10(7):e0133964. doi: 10.1371/journal.pone.0133964. eCollection 2015.

13.
14.

Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.

Artigalás O, Vanni T, Hutz MH, Ashton-Prolla P, Schwartz IV.

BMC Med. 2015 Jun 11;13:139. doi: 10.1186/s12916-015-0373-9.

15.

Clinical utility of exemestane in the treatment of breast cancer.

Zucchini G, Geuna E, Milani A, Aversa C, Martinello R, Montemurro F.

Int J Womens Health. 2015 May 27;7:551-63. doi: 10.2147/IJWH.S69475. eCollection 2015. Review.

16.

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Fan P, Maximov PY, Curpan RF, Abderrahman B, Jordan VC.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:245-63. doi: 10.1016/j.mce.2015.06.004. Epub 2015 Jun 5. Review.

PMID:
26052034
17.

Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.

Wu H, Guan S, Sun M, Yu Z, Zhao L, He M, Zhao H, Yao W, Wang E, Jin F, Xiao Q, Wei M.

PLoS One. 2015 May 11;10(5):e0126128. doi: 10.1371/journal.pone.0126128. eCollection 2015.

18.

5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.

Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL.

Cancer. 2015 Aug 1;121(15):2537-43. doi: 10.1002/cncr.29327. Epub 2015 Apr 30.

19.

Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

Djalalov S, Beca J, Amir E, Krahn M, Trudeau ME, Hoch JS.

Curr Oncol. 2015 Apr;22(2):84-96. doi: 10.3747/co.22.2120.

20.

Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.

Bodai BI, Tuso P.

Perm J. 2015 Spring;19(2):48-79. doi: 10.7812/TPP/14-241. Review.

Items per page

Supplemental Content

Write to the Help Desk